Azitra Plans IPO of 2.4M Common Shares
March 20, 2023 at 5:48 p.m. ET
By Stephen Nakrosis
Azitra Inc. on Monday said it plans an initial public offering of 2.4 million shares of common stock, with an expected price of $5 each.
The biopharmaceutical company said it is “focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products.”
Azitra…
By Stephen Nakrosis
Azitra Inc. on Monday said it plans an initial public offering of 2.4 million shares of common stock, with an expected price of $5 each.
The biopharmaceutical company said it is “focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products.”
Azitra said it entered into a joint development agreement with Bayer in Dec. 2019 “pursuant to which we agreed to the joint development of certain strains selected from our proprietary microbial library.”
Bios Equity Entities, Bayer Health Care LLC and Connecticut Innovations Inc. are listed among Azitra’s principal stockholders.
Azitra said it applied to list on the NYSE American under symbol AZTR.
ThinkEquity is listed as the offering’s underwriter.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
